A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer

PURPOSE: Docetaxel has a demonstrated survival benefit for patients with metastatic castration-resistant prostate cancer (mCRPC); however, 10% to 20% of patients discontinue docetaxel prematurely because of toxicity-induced adverse events, and the management of risk factors for toxicity remains a ch...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JCO Clin Cancer Inform
Egile Nagusiak: Seyednasrollah, Fatemeh, Koestler, Devin C., Wang, Tao, Piccolo, Stephen R., Vega, Roberto, Greiner, Russell, Fuchs, Christiane, Gofer, Eyal, Kumar, Luke, Wolfinger, Russell D., Kanigel Winner, Kimberly, Bare, Chris, Neto, Elias Chaibub, Yu, Thomas, Shen, Liji, Abdallah, Kald, Norman, Thea, Stolovitzky, Gustavo, Soule, Howard R., Sweeney, Christopher J., Ryan, Charles J., Scher, Howard I., Sartor, Oliver, Elo, Laura L., Zhou, Fang Liz, Guinney, Justin, Costello, James C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2017
Gaiak:
Original Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6874023/
https://ncbi.nlm.nih.gov/pubmed/30657384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/CCI.17.00018
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak